Pilot results of therapy of adult Ph-negative acute lymphoblastic leukemia according to the protocol of Research Group of Russian Hematological Centers ALL-2009


Cite item

Full Text

Abstract

Aim. To review results of 2-year experience in execution of the protocol on the treatment of adult acute Ph-negative lymphoblastic leukemia ALL-2009.
Material and methods. Of 111 patients registered in the study from November 2008 to December 2010 the analysis covered 96 patients from 23 hematological centers in 18 towns of the RF.
Results. Treatment according to the Protocol ALL-2009 resulted in achievement of a complete remission in 91.2% patients with low early lethality of 5.5%. Postremission lethality fell to 3.7% versus previous studies (22%). Overall 2-year survival and recurrence-free survival reached 77.6 and 78.4%, respectively. Detection of any chromosomic aberrations significantly affected recurrence-free survival: 74 vs 100% in patients with normal karyotype.
Conclusion. Protocol All-2009 demonstrates high efficacy in moderate toxicity and good reproducibility in any hematologic center.

About the authors

Elena Nikolaevna Parovichnikova

Email: elenap@blood.ru

G A Klyasova

V G Isaev

A N Sokolov

A V Kokhno

V V Troitskaya

E V Mavrina

E E Khodunova

E N Ustinova

E O Gribanova

S K Kravchenko

V V Ryzhko

T S Kaporskaya

O Yu Baranova

S N Bondarenko

A S Nizametdinova

E V Kondakova

T V Ryl'tsova

A N Alufer'eva

O S Samoylova

O P Skamorina

L V Gavrilova

A S Pristupa

N A Vopilina

T S Konstantinova

I V Kryuchkova

L V Anchukova

T S Tikunova

K D Kaplanov

V A Lapin

V A Tumakov

M N Kozmina

S A Chernysh

E I Podol'tseva

S M Kulikov

Yu R Davidyan

V G Savchenko

E N Parovichnikova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

G A Klyasova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

V G Isaev

Hematological Research Center, Moscow

Hematological Research Center, Moscow

A N Sokolov

Hematological Research Center, Moscow

Hematological Research Center, Moscow

A V Kokhno

Hematological Research Center, Moscow

Hematological Research Center, Moscow

V V Troitskaya

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E V Mavrina

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E E Khodunova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E N Ustinova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E O Gribanova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

S K Kravchenko

Hematological Research Center, Moscow

Hematological Research Center, Moscow

V V Ryzhko

Hematological Research Center, Moscow

Hematological Research Center, Moscow

T S Kaporskaya

Regional hospital, Irkutsk

Regional hospital, Irkutsk

O Yu Baranova

N.N. Blokhin Russian Cancer Research Center

N.N. Blokhin Russian Cancer Research Center

S N Bondarenko

State Medical University, St-Petersburg

State Medical University, St-Petersburg

A S Nizametdinova

City hospital N 17, St-Petersburg

City hospital N 17, St-Petersburg

E V Kondakova

Regional hospital, Surgut

Regional hospital, Surgut

T V Ryltsova

Regional hospital, Tula

Regional hospital, Tula

A N Aluferieva

Regional hospital, Samara

Regional hospital, Samara

O S Samoilova

Regional hospital, N. Novgorod

Regional hospital, N. Novgorod

O P Skamorina

Central hospital of GSS, Moscow

Central hospital of GSS, Moscow

L V Gavrilova

Regional hospital, Saransk

Regional hospital, Saransk

A S Pristupa

Regional hospital, Ryazan

Regional hospital, Ryazan

N A Vopilina

Regional hospital, Tambov

Regional hospital, Tambov

T S Konstantinova

Regional hospital, Ekaterinburg

Regional hospital, Ekaterinburg

I V Kryuchkova

Research Clinical Institute, Novosibirsk

Research Clinical Institute, Novosibirsk

L V Anchukova

Regional hospital, Vologda

Regional hospital, Vologda

T S Tikunova

Regional hospital, Belgorod

Regional hospital, Belgorod

K D Kaplanov

Regional hospital, Volgograd

Regional hospital, Volgograd

V A Lapin

Regional hospital, Yaroslavl

Regional hospital, Yaroslavl

V A Tumakov

Regional hospital, Ivanovo

Regional hospital, Ivanovo

M N Kozmina

Regional hospital, Orel

Regional hospital, Orel

S A Chernysh

S.P. Botkin City hospital, Moscow

S.P. Botkin City hospital, Moscow

E I Podoltseva

City hospital N 23, St-Petersburg

City hospital N 23, St-Petersburg

S M Kulikov

Hematological Research Center, Moscow

Hematological Research Center, Moscow

Yu R Davidyan

Hematological Research Center, Moscow

Hematological Research Center, Moscow

V G Savchenko

Hematological Research Center, Moscow

Hematological Research Center, Moscow

References

  1. Паровичникова Е. Н., Савченко В. Г., Давидян Ю. Р. и др. Итоги лечения острых лимфобластных лейкозов взрослых по протоколу ОЛЛ-2005 как основа для новых исследований. Тер. арх. 2009; 7: 8-16.
  2. Daves M. H., Hunger S., Linda S. B. et al. Longer time to the start of continuation therapy is associated with improved survival in high risk pediatric acute lumphoblastic leukemia(ALL): a report from the Children's Oncology Group (COG). Blood 2010; 116 (21): 1322 , abstr. 3223.
  3. Stive J. I., Buck G., Fielding A. et al. Inability to tolerate standard therapy is a major reason for poor outcome in older adults with acute lymphoblastic leukemia (ALL): results from international MRC/ECOG trial. Blood 2010; 116 (21): 218-219 , abstr. 493.
  4. Goekbuget N., Baumann A., Beck J. et al. PEG-Asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German multicenter study group for adult ALL (GMALL) study 07/2003. Blood 2010; 116 (2l): 219- 220 , abstr. 494.
  5. Rytting M. E., Kantarjian H., Thomas D. A. et al. Adolescent and young adult patients treated with modified augmented Berlin-Frankfurt-Muenster therapy. Blood 2010; 116 (21): 1333, abstr. 3250.
  6. Bassan R., Intermesoli T, Mascuilli A. et al. Pediatric type therapy including lineage-targeted methotrexate to improve eraly minimal residual disease response and survival in adult acute lymphoblastic leukemia (ALL): interim analysis of Northern Italy leukemia group study 10/07. Blood 2010; 116(21): 881- 882, abstr. 2131.

Copyright (c) 2011 Parovichnikova E.N., Klyasova G.A., Isaev V.G., Sokolov A.N., Kokhno A.V., Troitskaya V.V., Mavrina E.V., Khodunova E.E., Ustinova E.N., Gribanova E.O., Kravchenko S.K., Ryzhko V.V., Kaporskaya T.S., Baranova O.Y., Bondarenko S.N., Nizametdinova A.S., Kondakova E.V., Ryl'tsova T.V., Alufer'eva A.N., Samoylova O.S., Skamorina O.P., Gavrilova L.V., Pristupa A.S., Vopilina N.A., Konstantinova T.S., Kryuchkova I.V., Anchukova L.V., Tikunova T.S., Kaplanov K.D., Lapin V.A., Tumakov V.A., Kozmina M.N., Chernysh S.A., Podol'tseva E.I., Kulikov S.M., Davidyan Y.R., Savchenko V.G., Parovichnikova E.N., Klyasova G.A., Isaev V.G., Sokolov A.N., Kokhno A.V., Troitskaya V.V., Mavrina E.V., Khodunova E.E., Ustinova E.N., Gribanova E.O., Kravchenko S.K., Ryzhko V.V., Kaporskaya T.S., Baranova O.Y., Bondarenko S.N., Nizametdinova A.S., Kondakova E.V., Ryltsova T.V., Aluferieva A.N., Samoilova O.S., Skamorina O.P., Gavrilova L.V., Pristupa A.S., Vopilina N.A., Konstantinova T.S., Kryuchkova I.V., Anchukova L.V., Tikunova T.S., Kaplanov K.D., Lapin V.A., Tumakov V.A., Kozmina M.N., Chernysh S.A., Podoltseva E.I., Kulikov S.M., Davidyan Y.R., Savchenko V.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies